Beijing vascular health stratification-based intelligent life-long management of heart and vascular health

doi:10.3877/cma.j.issn.1674-0785.2019.11.015

Abstract

Abstract:

The traditional diagnosis and treatment model for cardiovascular diseases has shown its limitations in the face of a large population of patients with metabolic-related cardiovascular diseases. Based on the 2015 edition, the newly revised Beijing vascular health stratification is the basis for achieving intelligent life-long management of heart and vascular health to improve the prognosis of cardiovascular disease. The traditional model for the diagnosis and treatment of end-stage cardiovascular diseases will be replaced by this new type of health management model, so that the concept of ″preventive treatment of disease″ can be implemented, constructing a comprehensive and standardized service system covering nursing, pension, rehabilitation, diagnosis, and treatment. Thanks to the application of artificial intelligence, internet, and 5G, the largest chronic disease group affecting the population health of China-the burden of vascular-related diseases, which results in the largest chronic disease group in China, will be controlled unprecedentedly, thus contributing to the realization of the dream of healthy China.

Key words: Beijing vascular health stratification, Life-long management of heart health, Vascular health

Shantong Jiang, Hongyu Wang. Beijing vascular health stratification-based intelligent life-long management of heart and vascular health[J]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(11): 868-871.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2019.11.015

https://zhlcyszz.cma-cmc.com.cn/EN/Y2019/V13/I11/868

Figures/Tables 1

References 14

1	中国医药教育协会血管医学专业委员会, 中华医学会北京心血管疾病学分会血管专业学组. 北京大学医学部血管疾病社区防治中心中国血管健康评估系统应用指南(2018第三次报告) [J]. 中华医学杂志, 2018, 98(37): 2955-2967.
2	王宏宇. 推广血管健康理念,促进血管医学专业发展 [J]. 中国循环杂志, 2018, 33(10): 1026-1028.
3	胡盛寿, 高润霖, 刘力生, 等. 《中国心血管疾病报告2018》概要 [J]. 中国循环杂志, 2019, 34(3): 209-220.
4	李春燕, 简伟研. 中老年人心血管疾病经济负担——基于中国健康与养老追踪调查的实证分析 [J]. 中国卫生政策研究, 2017, 10(5): 75-80.
5	Yip W, Hsiao WC. Non-evidence-based policy: how effective is China′s new cooperative medical scheme in reducing medical impoverishment? [J]. Soc Sci Med, 2009, 68(2): 201-209.
6	Al′Aref SJ, Anchouche K, Singh G, et al. Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging [J]. Eur Heart J, 2019, 40(24): 1975-1986.
7	Krittanawong C, Johnson KW, Rosenson RS, et al. Deep learning for cardiovascular medicine: a practical primer [J]. Eur Heart J, 2019, 40(25): 2058-2073.
8	Shameer K, Johnson KW, Glicksberg BS, et al. Machine learning in cardiovascular medicine: are we there yet? [J]. Heart, 2018, 104(14): 1156-1164.
9	Schoenhagen P, Mehta N. Big data, smart computer systems, and doctor-patient relationship [J]. Eur Heart J, 2017, 38(7): 508-510.
10	Hernesniemi JA, Mahdiani S, Tynkkynen JA, et al. Extensive phenotype data and machine learning in prediction of mortality in acute coronary syndrome-the MADDEC study [J]. Ann Med, 2019, 51(2): 156-163.
11	Motwani M, Dey D, Berman DS, et al. Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease: a 5-year multicentre prospective registry analysis [J]. Eur Heart J, 2017, 38(7): 500-507.
12	Alsharqi M, Upton R, Mumith A, et al. Artificial intelligence: a new clinical support tool for stress echocardiography [J]. Expert Rev Med Devices, 2018, 15(8): 513-515.
13	Alsharqi M, Woodward WJ, Mumith JA, et al. Artificial intelligence and echocardiography [J]. Echo Res Pract, 2018, 5(4): R115-R125.
14	Gandhi S, Mosleh W, Shen J, et al. Automation, machine learning, and artificial intelligence in echocardiography: a brave new world [J]. Echocardiography, 2018, 35(9): 1402-1418.

级别		描述
Ⅰ级		正常：结构和功能均正常
Ⅱ级		动脉内皮功能障碍：无影像学证实的粥样硬化［FMD≤10%和（或）RHI<1.67］
Ⅲ级		动脉僵硬期：无影像学证实的粥样硬化（CF-PWV>9 m/s，CAVI>9）
Ⅳ级		结构性血管病变早期：影像学证实的动脉粥样硬化管腔狭窄<50%
?	Ⅳa	动脉弹性和（或）内皮功能正常［CF-PWV≤9 m/s和（或）CAVI≤9；FMD>10%和（或）RHI≥1.67］
?	Ⅳb	动脉弹性和（或）内皮功能降低［CF-PWV>9 m/s和（或）CAVI>9；FMD≤10%和（或）RHI<1.67］
Ⅴ级		结构性血管病变中期：影像学证实的动脉粥样硬化管腔狭窄50%~75%
?	Ⅴa	动脉弹性和（或）内皮功能正常［CF-PWV≤9 m/s和（或）CAVI≤9；FMD>10%和（或）RHI≥1.67］
?	Ⅴb	动脉弹性和（或）内皮功能降低［CF-PWV>9 m/s和（或）CAVI>9；FMD≤10%和（或）RHI<1.67］
Ⅵ级		结构性血管病变晚期：影像学证实的动脉粥样硬化管腔狭窄>75%（心、脑、肾、下肢血管）
?	Ⅵa	动脉弹性和（或）内皮功能正常［CF-PWV≤9 m/s和（或）CAVI≤9；FMD>10%和（或）RHI≥1.67］
?	Ⅵb	动脉弹性和（或）内皮功能降低［CF-PWV>9 m/s和（或）CAVI>9；FMD≤10%和（或）RHI<1.67］
Ⅶ级		临床血管事件期（需紧急住院）：血管性猝死、急性冠状动脉综合征、脑血管意外、下肢动脉闭塞

级别		描述
Ⅰ级		正常：结构和功能均正常
Ⅱ级		动脉内皮功能障碍：无影像学证实的粥样硬化［FMD≤10%和（或）RHI<1.67］
Ⅲ级		动脉僵硬期：无影像学证实的粥样硬化（CF-PWV>9 m/s，CAVI>9）
Ⅳ级		结构性血管病变早期：影像学证实的动脉粥样硬化管腔狭窄<50%
?	Ⅳa	动脉弹性和（或）内皮功能正常［CF-PWV≤9 m/s和（或）CAVI≤9；FMD>10%和（或）RHI≥1.67］
?	Ⅳb	动脉弹性和（或）内皮功能降低［CF-PWV>9 m/s和（或）CAVI>9；FMD≤10%和（或）RHI<1.67］
Ⅴ级		结构性血管病变中期：影像学证实的动脉粥样硬化管腔狭窄50%~75%
?	Ⅴa	动脉弹性和（或）内皮功能正常［CF-PWV≤9 m/s和（或）CAVI≤9；FMD>10%和（或）RHI≥1.67］
?	Ⅴb	动脉弹性和（或）内皮功能降低［CF-PWV>9 m/s和（或）CAVI>9；FMD≤10%和（或）RHI<1.67］
Ⅵ级		结构性血管病变晚期：影像学证实的动脉粥样硬化管腔狭窄>75%（心、脑、肾、下肢血管）
?	Ⅵa	动脉弹性和（或）内皮功能正常［CF-PWV≤9 m/s和（或）CAVI≤9；FMD>10%和（或）RHI≥1.67］
?	Ⅵb	动脉弹性和（或）内皮功能降低［CF-PWV>9 m/s和（或）CAVI>9；FMD≤10%和（或）RHI<1.67］
Ⅶ级		临床血管事件期（需紧急住院）：血管性猝死、急性冠状动脉综合征、脑血管意外、下肢动脉闭塞

Please choose a citation manager

Content to export